Adding a second medication versus increasing the dose of current treatment for Crohn's disease

This trial is testing whether a combination approach—keeping your current TNF inhibitor dose the same while adding a second oral medication called upadacitinib—works better than simply increasing your TNF inhibitor dose. The study includes adults with Crohn's disease who have been on a TNF inhibitor for at least 12 weeks but aren't getting the full benefit they need. Researchers want to see if this dual-medication strategy helps more people achieve better control of their disease.

Some people with Crohn's disease don't respond well enough to standard doses of TNF inhibitors alone. Doctors traditionally respond by increasing the TNF inhibitor dose, but this trial is testing whether adding a second type of medication might work just as well or better, while potentially being safer.